Weight regain after stopping GLP-1 therapy reflects the underlying biology of your appetite regulation pathways rather than a failure of the medication
This ensures the program we help you access is safe for your unique physiology
Particularly, the latter, the GLP-1 receptor agonists, either alone or in various combinations, are so powerful that treatment allows more than 2/3 of type 2 diabetes patients to reach glycemic targets
The outcomes highlight a revolutionary shift in obesity and weight loss care, offering organizations a responsible way to cover GLP-1s for weight loss, while reducing reliance and curbing total costs for the medications
doi:10.1172/JCI116186 Willms B, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Nauck MA